ECSP23048136A - Compuestos de indazol como inhibidores de cinasas - Google Patents

Compuestos de indazol como inhibidores de cinasas

Info

Publication number
ECSP23048136A
ECSP23048136A ECSENADI202348136A ECDI202348136A ECSP23048136A EC SP23048136 A ECSP23048136 A EC SP23048136A EC SENADI202348136 A ECSENADI202348136 A EC SENADI202348136A EC DI202348136 A ECDI202348136 A EC DI202348136A EC SP23048136 A ECSP23048136 A EC SP23048136A
Authority
EC
Ecuador
Prior art keywords
kinase inhibitors
indazole compounds
compounds
indazole
disclosed
Prior art date
Application number
ECSENADI202348136A
Other languages
English (en)
Inventor
Robert Hudkins
Daniel Bensen
Original Assignee
Tyra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyra Biosciences Inc filed Critical Tyra Biosciences Inc
Publication of ECSP23048136A publication Critical patent/ECSP23048136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En el presente documento se divulgan compuestos y métodos para tratar enfermedades y/o afecciones asociadas con la inhibición de FGFR.
ECSENADI202348136A 2020-12-30 2023-06-26 Compuestos de indazol como inhibidores de cinasas ECSP23048136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063132031P 2020-12-30 2020-12-30
US202163216879P 2021-06-30 2021-06-30

Publications (1)

Publication Number Publication Date
ECSP23048136A true ECSP23048136A (es) 2023-09-29

Family

ID=80168316

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202348136A ECSP23048136A (es) 2020-12-30 2023-06-26 Compuestos de indazol como inhibidores de cinasas

Country Status (16)

Country Link
US (3) US12264149B2 (es)
EP (1) EP4271673A1 (es)
JP (2) JP7791196B2 (es)
KR (1) KR20230152654A (es)
AU (1) AU2021411587B2 (es)
CA (1) CA3205986A1 (es)
CL (1) CL2023001951A1 (es)
CO (1) CO2023008689A2 (es)
CR (1) CR20230325A (es)
EC (1) ECSP23048136A (es)
IL (1) IL304014A (es)
MX (1) MX2023007793A (es)
PE (1) PE20240687A1 (es)
TW (1) TW202241906A (es)
WO (1) WO2022147246A1 (es)
ZA (1) ZA202306559B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
EP4547670A1 (en) * 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
TW202416961A (zh) * 2022-06-29 2024-05-01 美商泰拉生物科學公司 吲唑化合物
JP2025529161A (ja) 2022-08-30 2025-09-04 タイラ・バイオサイエンシーズ・インコーポレイテッド 活性化ｆｇｆｒ３遺伝子変化を有する固形腫瘍を処置する方法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
WO2024138112A1 (en) * 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
CN120265624A (zh) * 2022-12-30 2025-07-04 江苏亚虹医药科技股份有限公司 吡唑稠环化合物及其制备方法和用途
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN119306723A (zh) * 2023-07-13 2025-01-14 长春金赛药业有限责任公司 吲唑类fgfr2/3选择性抑制剂、药物组合物及其应用
WO2025021033A1 (zh) * 2023-07-21 2025-01-30 长春金赛药业有限责任公司 成纤维细胞生长因子受体抑制剂、药物组合物及其应用
WO2025021997A1 (en) 2023-07-27 2025-01-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts New map4k1 inhibitors
WO2025061029A1 (en) * 2023-09-18 2025-03-27 3H Pharmaceuticals Co., Ltd. Fgfr inhibitors and methods of use thereof
WO2025064744A1 (en) 2023-09-22 2025-03-27 Tyra Biosciences, Inc. Tyra-300 (5-[(1r)-1-(3,5-dichloro-4-pyridyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-1h-indazole ) in combination with a pd-1 or pd-l1 antagonist for use in the treatment of cancer
WO2025129014A1 (en) * 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025170959A1 (en) 2024-02-05 2025-08-14 Tyra Biosciences, Inc. Combination of the fgfr 3 inhibitor tyra-300 and a nectin-4 targeting agent-drug conjugate for use in the treatment of cancer
WO2025199217A1 (en) 2024-03-19 2025-09-25 Tyra Biosciences, Inc. Pharmaceutical compositions
WO2026020109A1 (en) * 2024-07-19 2026-01-22 Tyra Biosciences, Inc. Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer
WO2026035809A1 (en) * 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS62135832A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62135830A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料及びその処理方法
JPS62135834A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62135835A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62136651A (ja) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
JPS62136654A (ja) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPS62136650A (ja) 1985-12-11 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料及びその処理方法
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
GB8808433D0 (en) 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6391872B1 (en) 1997-11-04 2002-05-21 Pfizer Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
US6716978B2 (en) 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
BR0313396A (pt) 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005040157A2 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
US20050203151A1 (en) 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7834036B2 (en) 2005-03-04 2010-11-16 Merck Sharp & Dohme Corp Fused-aromatic compounds having anti-diabetic activity
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
WO2007050124A1 (en) 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US20080027052A1 (en) 2006-07-10 2008-01-31 Sharon Moe Methods for treating cystic kidney disease
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
EP2134683A2 (en) 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
KR20100017359A (ko) 2007-04-25 2010-02-16 엑셀리시스, 인코포레이티드 카제인 키나제 ⅱ （ｃｋ２）조절제로서의 피리미디논
AU2008248186B2 (en) 2007-05-07 2014-02-06 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2368876A1 (en) 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
WO2011109551A2 (en) 2010-03-03 2011-09-09 Calcimedica Inc. Compounds that modulate intracellular calcium
JP5763937B2 (ja) 2010-03-10 2015-08-12 Ａｇｃセイミケミカル株式会社 液晶化合物、その製造方法、液晶組成物および液晶電気光学素子
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012160015A1 (en) 2011-05-23 2012-11-29 Sanofi Process for the preparation of deuterated compounds containing n-alkyl groups
CN102243505B (zh) 2011-07-07 2013-08-14 矽力杰半导体技术(杭州)有限公司 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路
JP6036693B2 (ja) 2011-08-05 2016-11-30 アステラス製薬株式会社 新規ｆｇｆｒ４変異体の検出法
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2763990B1 (en) 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP3567029A1 (en) 2011-09-09 2019-11-13 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CN103420906B (zh) * 2012-05-21 2015-09-09 南京圣和药业股份有限公司 新型酪氨酸蛋白激酶抑制剂
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
US20140213538A1 (en) 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
KR101648141B1 (ko) 2013-06-11 2016-08-12 제일모직 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
WO2015035415A1 (en) 2013-09-09 2015-03-12 Nantomics, Llc Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2924843A1 (en) 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
EP3080298B1 (en) 2013-12-11 2018-10-31 AccuraGen Holdings Limited Methods for detecting rare sequence variants
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
EP3102705A4 (en) 2014-02-04 2017-10-25 Mayo Foundation for Medical Education and Research Method of identifying tyrosine kinase receptor rearrangements in patients
KR20160138494A (ko) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr 융합물
WO2015154169A1 (en) 2014-04-09 2015-10-15 The University Of British Columbia Binding function3 (bf3) site compounds as therapeutics and methods for their use
WO2015169425A1 (en) 2014-05-09 2015-11-12 Merck Patent Gmbh Liquid-crystalline medium and high-frequency components comprising same
US10045979B2 (en) 2014-05-19 2018-08-14 Merial Inc. Anthelmintic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
JP2017529332A (ja) 2014-08-28 2017-10-05 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法
KR20170082590A (ko) 2014-11-11 2017-07-14 메르크 파텐트 게엠베하 바이메소젠성 화합물 및 메소젠성 매질
JP2018027019A (ja) 2014-11-26 2018-02-22 国立研究開発法人国立がん研究センター 胆道がんにおける新規治療標的融合遺伝子
EP3237638B1 (en) 2014-12-24 2020-01-15 F.Hoffmann-La Roche Ag Therapeutic, diagnostic and prognostic methods for cancer of the bladder
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
CN106317023A (zh) 2015-07-10 2017-01-11 中国科学院上海药物研究所 吲唑类化合物的制备方法和用途
WO2017024968A1 (zh) 2015-08-07 2017-02-16 南京明德新药研发股份有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
MX2018004879A (es) 2015-10-22 2019-02-28 Selvita S A Nuevos derivados de piridona y su uso como inhibidores de quinasas.
EP3424702A4 (en) 2016-03-02 2019-10-23 JNC Corporation LAMINATE, ELECTRONIC DEVICE AND MANUFACTURING METHOD FOR LAMINATE
WO2017150587A1 (ja) 2016-03-02 2017-09-08 Jnc株式会社 低熱膨張部材用組成物、低熱膨張部材、電子機器、低熱膨張部材の製造方法
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
US20190177617A1 (en) 2016-05-12 2019-06-13 Merck Patent Gmbh Bimesogenic compounds and mesogenic media
US11124628B2 (en) 2016-08-30 2021-09-21 Dow Global Technologies Llc Method of attenuating concerntration of acrolein
JP6589795B2 (ja) 2016-09-27 2019-10-16 信越化学工業株式会社 スルホニウム塩、レジスト組成物及びパターン形成方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2019018795A1 (en) 2017-07-20 2019-01-24 Yumanity Therapeutics COMPOUNDS AND USES THEREOF
US11787766B2 (en) 2017-08-18 2023-10-17 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
US11795162B2 (en) 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
WO2019209948A1 (en) 2018-04-25 2019-10-31 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020051207A2 (en) 2018-09-04 2020-03-12 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and methods of use
KR102127006B1 (ko) 2018-12-06 2020-06-25 한국생산기술연구원 피리미딘계 작용기 함유 단분자 화합물, 상기 화합물의 광가교물을 포함한 유기물층 및 이를 포함하는 유기전자소자
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
IN201941011265A (es) * 2019-03-22 2020-09-25
WO2020228756A1 (zh) 2019-05-14 2020-11-19 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN112812014B (zh) 2019-11-15 2024-05-10 石家庄诚志永华显示材料有限公司 化合物、液晶组合物、液晶显示器
CN113179640B (zh) 2019-11-26 2024-06-25 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
TW202136253A (zh) 2019-12-19 2021-10-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20230128972A1 (en) 2020-01-31 2023-04-27 Atomwise Inc. Anat Inhibitors and Methods of Use Thereof
KR20220141328A (ko) 2020-02-12 2022-10-19 큐라데브 파마 프라이버트 리미티드 소분자 sting 길항제
WO2021178780A1 (en) 2020-03-06 2021-09-10 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
WO2021183970A1 (en) 2020-03-13 2021-09-16 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
MX2022013861A (es) 2020-05-06 2023-02-22 Servier Lab Nuevos inhibidores macrociclicos de la quinasa de lrrk2.
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
JP2024512449A (ja) 2021-03-18 2024-03-19 レ ラボラトワール セルヴィエ 大環状ｌｒｒｋ２キナーゼ阻害剤
CR20230449A (es) 2021-03-19 2023-11-23 Arvinas Operations Inc Compuestos a base de indazol y métodos de uso asociados
US20240316022A1 (en) * 2021-06-30 2024-09-26 Tyra Biosciences, Inc. Indazole compounds
CA3247536A1 (en) 2022-04-04 2023-10-12 Brenig Therapeutics, Inc. LEUCINE-RICH KINASE 2 REPETITION INHIBITORS
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
TW202416961A (zh) 2022-06-29 2024-05-01 美商泰拉生物科學公司 吲唑化合物
JP2025529161A (ja) 2022-08-30 2025-09-04 タイラ・バイオサイエンシーズ・インコーポレイテッド 活性化ｆｇｆｒ３遺伝子変化を有する固形腫瘍を処置する方法

Also Published As

Publication number Publication date
CO2023008689A2 (es) 2023-09-29
CL2023001951A1 (es) 2023-12-01
IL304014A (en) 2023-08-01
WO2022147246A1 (en) 2022-07-07
MX2023007793A (es) 2023-09-22
AU2021411587B2 (en) 2024-10-10
JP7791196B2 (ja) 2025-12-23
US20240109865A1 (en) 2024-04-04
ZA202306559B (en) 2025-09-25
US12071428B2 (en) 2024-08-27
AU2021411587A1 (en) 2023-07-06
JP2024502433A (ja) 2024-01-19
CA3205986A1 (en) 2022-07-07
US12264149B2 (en) 2025-04-01
PE20240687A1 (es) 2024-04-10
TW202241906A (zh) 2022-11-01
US20240208941A1 (en) 2024-06-27
EP4271673A1 (en) 2023-11-08
CR20230325A (es) 2023-12-11
JP2026048777A (ja) 2026-03-17
US20250340533A1 (en) 2025-11-06
KR20230152654A (ko) 2023-11-03

Similar Documents

Publication Publication Date Title
CO2023008689A2 (es) Compuestos de indazol como inhibidores de cinasas
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CO2021008224A2 (es) Inhibidores de kif18a
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
CL2018003511A1 (es) Derivados de pirazolopirimidina como inhibidor de quinasa.
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
MX2017000806A (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
MX2024004162A (es) Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico.
MX2018010028A (es) Derivados de carboxamida utiles como inhibidores de rsk.
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
MX2024015477A (es) Compuestos de indazol
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
MX383930B (es) Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2017009246A (es) Farmaco de combinacion.
CO2025003263A2 (es) Inhibidores de kif18a y usos de estos
MX2022002443A (es) Compuestos inhibidores de perk.
CL2024001535A1 (es) Quinolinas y azaquinolinas como inhibidores de cd38
CO2024009144A2 (es) Inhibidores de cinasa met
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
BR112019008622A2 (pt) método para tratar uma condição